• Skip to primary navigation
  • Skip to main content
  • Skip to footer
PanTher Therapeutics

PanTher Therapeutics

  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact
homePress ReleasePanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia

PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia

August 4, 2021 Press Release

PanTher announced today that it received approval from the Human Research Ethics Committee (HREC) to open a Phase 1 clinical trial of PTM-101 in Australia. PTM-101 is being developed for the treatment of pancreatic cancer. The company also announced today the appointment of J. Marc Pipas, MD, as Chief Medical Officer and the establishment of its clinical advisory board. Dr. Pipas, a veteran GI oncologist and clinical trialist who has assisted in the development of multiple oncology agents from Phase 1 trials through commercialization (including ONIVYDE®, which received approval from the FDA for pancreatic cancer and was subsequently sold to Ipsen Pharmaceuticals for $1 billion), will direct PanTher’s clinical development programs.

Footer

Twitter LinkedIn

PanTher Therapeutics, Inc

191 Dexter Ave
Watertown, MA, 02472

PanTher Therapeutics © 2022 All Rights Reserved

Terms of Use Privacy Policy Cookie Policy Accessibility Statement

logo
  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact